Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

42623

Sigma-Aldrich

Butyryl-L-carnitine

≥97.0% (TLC)

Sinonimo/i:

(2R)-3-Carboxy-N,N,N-trimethyl-2-(1-oxobutoxy)-1-propanaminium inner salt, Butanoyl-L-carnitine, C4-Carnitine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C11H21NO4
Numero CAS:
25576-40-3
Peso molecolare:
231.29
Numero MDL:
MFCD01674827
Codice UNSPSC:
41116107
ID PubChem:
329756249
NACRES:
NA.26

Nome del prodotto

Butyryl-L-carnitine, ≥97.0% (TLC)

Livello qualitativo

100

Saggio

≥97.0% (TLC)

Stato

powder, crystals or chunks

Attività ottica

[α]/D -23±2°, c = 1 in H2O

Colore

white to off-white

Temperatura di conservazione

2-8°C

Stringa SMILE

C[N+](C)(C)C[C@H](OC(CCC)=O)CC([O-])=O

InChI

1S/C11H21NO4/c1-5-6-11(15)16-9(7-10(13)14)8-12(2,3)4/h9H,5-8H2,1-4H3/t9-/m1/s1
QWYFHHGCZUCMBN-SECBINFHSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni


  • Lead exposure induces metabolic reprogramming in rat models.: This study by Mani MS et al. investigates the metabolic effects of lead exposure in rat models, focusing on the biochemical pathways affected. The research highlights the role of butyryl-ʟ-carnitine in counteracting lead-induced metabolic disruptions, suggesting its potential therapeutic applications in mitigating heavy metal toxicity (Mani et al., 2020).

Azioni biochim/fisiol

Butyrylcarnitine is elevated in patients with Acyl-CoA dehydrogenase, short-chain (SCAD) deficiency, in infants with acute acidosis and generalized muscle weakness and in middle-aged patients with chronic myopathy localized in muscle; very long chain Acyl-CoA dehydrogenase deficiency, and celiac disease.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCCB3203
BCBZ6118
BCBP1876V
BCBP1876

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

R Golan et al.
International journal of andrology, 6(4), 349-357 (1983-08-01)
Bioautography of human semen demonstrated the presence of L-carnitine, acetylcarnitine, propionylcarnitine and C4-acylcarnitines (butyrylcarnitines). In studies designed to ascertain the organs secreting these compounds into semen it was found that: Quantitative analyses of semen obtained pre- and post-vasectomy showed markedly
Sarah P Young et al.
Clinica chimica acta; international journal of clinical chemistry, 337(1-2), 103-113 (2003-10-22)
Homozygosity and compound heterozygosity for the short chain acyl-CoA dehydrogenase (SCAD) gene sequence variants 625G-->A and 511C-->T are associated with ethylmalonic aciduria (EMA), a biochemical indicator of SCAD deficiency. The clinical and biochemical implications of these variants are not fully
S Benito et al.
The Analyst, 143(18), 4448-4458 (2018-08-29)
Pediatric chronic kidney disease (CKD) is a clinical syndrome characterized by renal hypofunction occurring due to gradual and irreversible kidney damage that can further progress over time. New biomarkers may help early diagnosis of pediatric patients suffering from CKD and
A Bhala et al.
The Journal of pediatrics, 126(6), 910-915 (1995-06-01)
We identified two additional patients with short-chain acyl-coenzyme A (CoA), further characterized the clinical and biochemical features of this defect, and compared it with other fatty acid oxidation defects. We have measured the in vitro short-chain acyl-coenzyme A dehydrogenase (SCAD)
Josiane Joseph et al.
Metabolites, 8(4) (2018-10-05)
Duchenne muscular dystrophy (DMD) is a musculoskeletal disorder that causes severe morbidity and reduced lifespan. Individuals with DMD have an X-linked mutation that impairs their ability to produce functional dystrophin protein in muscle. No cure exists for this disease and
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.